Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4018 participants.
Also called NCT01944800
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 4,018 participants
- Registry
-
NCT01944800 -
2013-002272-40
-
- Other papers using this trial's data
- Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy
- Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial
- Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
- Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes
- Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes
- Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy
- Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial
- The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes
- Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial
- Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk
- Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate
- Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
- Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
- Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial
- Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany, Italy
- Registry status
- Completed
Technical summary
Registry record NCT01944800. Randomized; single masking; primary purpose treatment. Start 2013-09-15 (actual); primary completion 2019-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
- Acronym
- ISAR-REACT 5
- Condition
- Acute Coronary Syndrome (ACS)
- Intervention (Drug)
- Ticagrelor
- Intervention (Drug)
- Prasugrel
- Lead sponsor
- Deutsches Herzzentrum Muenchen
- Collaborator
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Record details
- Record id
cardio:ct-nct01944800- Content hash
e4ee8bf123f95ac27bd465324e5dffd9353584ba2021dbe2045a2d1e72f58641